Veloxis Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
HORSHOLM, Denmark, Aug. 4, 2011 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), formerly LifeCycle Pharma, today announced that William J. Polvino, M.D., president and chief executive officer, will present at the Canaccord Genuity Annual Growth Conference at 4 p.m. EDT on Tuesday, August 9, at the InterContinental Hotel in Boston. Dr. Polvino will provide an overview of the company and its lead Phase 3 candidate, LCP-Tacro™, to prevent organ transplant rejection. He will also discuss recently-announced top-line results of the first Phase 3 trial in stable kidney transplant patients.
About Veloxis Pharmaceuticals A/S
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability -- at low-scale up costs -- not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
For U.S. investor and media contacts:
John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S
SOURCE Veloxis Pharmaceuticals A/S